 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
19 News |  |
- | quinapril hydrochloride / Generic mfg.
Journal: Benefit and risk evaluation of quinapril hydrochloride. (Pubmed Central) - May 22, 2023
However, a lack of ample recent clinical trials and post-marketing data investigating the efficacy of quinapril in large cohorts has resulted in limited use in clinical practice. Quinapril may be an effective antihypertensive option for elderly populations as well as those who cannot tolerate the side effects profiles of other ACE inhibitors and as an additional treatment option for patients with heart failure with preserved ejection fraction.
- || Chantix (varenicline) / Pfizer, hydromorphone hydrochloride / Generic mfg., quinapril hydrochloride / Generic mfg.
TRUST THE SCIENCE??? These of a few of Pfizer recalls…. 1. Bextra 2. Chantix 3. Accupril 4. Accuretic 5. Alvogen 6. Activase 7. Hydromorphone HCl Injection 8. 0.9% Sodium Chloride Injection 9. Succinylcholine Chloride 10. Norepinephrine Bitartrate Injection (Twitter) - Aug 30, 2022
- ||| quinapril hydrochloride / Generic mfg.
Public advisory: Pfizer recalls Accupril blood pressure tablets due to a nitrosamine impurity https://t.co/wItpcFxBQG (Twitter) - Apr 21, 2022
- | quinapril hydrochloride / Generic mfg.
Journal: Binder jetting 3D printing of challenging medicines: from low dose tablets to hydrophobic molecules. (Pubmed Central) - Mar 23, 2022
The approach is demonstrated using two model APIs: hydrophilic quinapril hydrochloride (QHCl, logP = 1.4) and hydrophobic clotrimazole (CLO, logP = 5.4)...The tablets could be scaled and obtained in predesigned shapes and sizes. The proposed method may find its application in the early stages of drug development where high flexibility of the formulation is required and the amount of available API is limited.
- ||| hydrochlorothiazide / Generic mfg., quinapril hydrochloride / Generic mfg.
Quinapril Hydrochloride and Hydrochlorothiazide Tablets by Pfizer: Recall - Due to N-NitrosoQuinapril Content https://t.co/FMuNNFdQVf (Twitter) - Mar 23, 2022
- | valsartan / Generic mfg., gliclazide / Generic mfg.
Preclinical, Journal: In Vitro Investigation of Binding Interactions between Albumin-Gliclazide Model and Typical Hypotensive Drugs. (Pubmed Central) - Feb 2, 2022
The analysis of the thermodynamic parameters indicated the spontaneity of the reaction and emphasized the role of hydrogen bonding and van der Waals forces in these interactions. The secondary structure of the BSA remained almost unaffected.
- | Journal: Drugs for chronic heart failure. (Pubmed Central) - Jul 14, 2021
The secondary structure of the BSA remained almost unaffected. No abstract available
- | Journal: Comparison chart: Some drugs for HFrEF. (Pubmed Central) - Jul 14, 2021
No abstract available No abstract available
- | valsartan / Generic mfg.
Journal: Comparison table: Some drugs for HFrEF. (Pubmed Central) - Mar 24, 2021
No abstract available No abstract available
- valsartan / Generic mfg.
[VIRTUAL] Rostral Ventrolateral Medullary Compression: A Rare but a Cardinal Cause of Refractory Hypertension (RfHTN) (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1585;
Her medications included: hydralazine, lopressor, procardia, demadex, accupril, diovan, catapres and aldactone...Renal ultrasound/doppler, captopril scan, and angiograms showed no renal artery stenosis or coactation of the aorta, and 24-hour urine metanephrines were normal...Minoxidil was initiated and procardia and lopressor were maintained, with no effect on BP...Discussion NVC is related to neurogenic HTN when occurring in the RVL medulla. This case highlights that brain MRI be performed in patients with intractable resistant HTN when all other secondary causes are ruled out.
- || quinapril hydrochloride / Generic mfg., lisinopril / Generic mfg.
Thanks Dr. Bhatt. I use to sell Accupril for Parke-Davis, and Zestril for AZ. (Twitter) - Jul 11, 2020
- | Trial completion, Surgery: Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (clinicaltrials.gov) - May 2, 2017
P4, N=291, Completed, Sponsor: University of Nebraska
This case highlights that brain MRI be performed in patients with intractable resistant HTN when all other secondary causes are ruled out. Enrolling by invitation --> Completed
- Trial completion: SMAC AF: Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF (clinicaltrials.gov) - Jan 31, 2017
P4, N=184, Completed, Sponsor: Nova Scotia Health Authority
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- Trial primary completion date, Surgery: Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (clinicaltrials.gov) - May 25, 2016
P4, N=300, Enrolling by invitation, Sponsor: University of Nebraska
Active, not recruiting --> Completed Trial primary completion date: Apr 2016 --> Nov 2016
- Enrollment closed, Trial primary completion date: SMAC AF: Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF (clinicaltrials.gov) - Feb 3, 2016
P4, N=184, Active, not recruiting, Sponsor: Nova Scotia Health Authority
Trial primary completion date: Apr 2016 --> Nov 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Oct 2016
- Enrollment open, Trial initiation date, Trial primary completion date, Surgery: Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (clinicaltrials.gov) - Dec 4, 2015
P4, N=300, Enrolling by invitation, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Oct 2016 Not yet recruiting --> Enrolling by invitation | Initiation date: Oct 2015 --> Jun 2015 | Trial primary completion date: Jan 2016 --> Apr 2016
- Trial primary completion date: SMAC AF: Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF (clinicaltrials.gov) - Oct 7, 2015
P4, N=184, Recruiting, Sponsor: Nova Scotia Health Authority
Not yet recruiting --> Enrolling by invitation | Initiation date: Oct 2015 --> Jun 2015 | Trial primary completion date: Jan 2016 --> Apr 2016 Trial primary completion date: Jun 2015 --> Nov 2015
- Trial primary completion date: SMAC AF: Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF (clinicaltrials.gov) - Jan 28, 2015
P4, N=184, Recruiting, Sponsor: Capital District Health Authority, Canada
Trial primary completion date: Jun 2015 --> Nov 2015 Trial primary completion date: Dec 2014 --> Jun 2015
- ||| Trial initiation date, Trial primary completion date, Surgery: Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (clinicaltrials.gov) - Dec 5, 2014
P4, N=300, Not yet recruiting, Sponsor: University of Nebraska
Trial primary completion date: Dec 2014 --> Jun 2015 Initiation date: Oct 2012 --> Oct 2015 | Trial primary completion date: Jan 2014 --> Jan 2016
- | New P4 trial, Surgery: Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (clinicaltrials.gov) - Aug 19, 2012
P4, N=300, Not yet recruiting, Sponsor: University of Nebraska